Monjuvi

Active Ingredient(s): Tafasitamab-cxix
FDA Approved: * July 31, 2020
Pharm Company: * MORPHOSYS US INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Monjuvi Overview

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1] Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby.[2] The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swellin...

Read more Monjuvi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tafasitamab

Recent Monjuvi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tafasitamab-cxix
  • Injection: 12mg/kg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Tafasitamab-cxix or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA